{"id":"piperacillin-extended-infusion","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-8","effect":"Nausea"},{"rate":"2-5","effect":"Rash"},{"rate":"5-15","effect":"Phlebitis at infusion site"},{"rate":"1-3","effect":"Hypersensitivity reactions"},{"rate":"1-2","effect":"Clostridium difficile-associated diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Piperacillin is an extended-spectrum ureidopenicillin that penetrates bacterial cell walls and irreversibly inhibits transpeptidase enzymes responsible for cross-linking peptidoglycan strands. Extended infusion administration maintains bactericidal concentrations above the minimum inhibitory concentration for a longer duration, improving efficacy against susceptible gram-negative and gram-positive bacteria. This dosing strategy is particularly effective for treating serious infections caused by Pseudomonas aeruginosa and other resistant pathogens.","oneSentence":"Piperacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:25.793Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious bacterial infections including pneumonia, intra-abdominal infections, and urinary tract infections"},{"name":"Pseudomonas aeruginosa infections"},{"name":"Febrile neutropenia in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT07484633","phase":"PHASE4","title":"A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients.","status":"NOT_YET_RECRUITING","sponsor":"Semmelweis University","startDate":"2026-04","conditions":"Infection, Sepsis, NICU","enrollment":110},{"nctId":"NCT06954129","phase":"PHASE4","title":"A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-01-28","conditions":"Acute Kidney Injury","enrollment":750},{"nctId":"NCT06184659","phase":"PHASE4","title":"Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis","status":"RECRUITING","sponsor":"Scandinavian Critical Care Trials Group","startDate":"2025-06-26","conditions":"Sepsis, Septic Shock","enrollment":5800},{"nctId":"NCT06972537","phase":"NA","title":"A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia","status":"RECRUITING","sponsor":"Shandong University","startDate":"2024-07-24","conditions":"Pneumonia","enrollment":42},{"nctId":"NCT02820987","phase":"PHASE3","title":"PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2016-09-27","conditions":"Septic Shock","enrollment":119},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT03897582","phase":"","title":"Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study","status":"RECRUITING","sponsor":"Centre Hospitalier de Valenciennes","startDate":"2019-02-22","conditions":"Beta-lactam, Continuous Renal Replacement Therapy, Pneumonia","enrollment":65},{"nctId":"NCT05565222","phase":"PHASE3","title":"Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-03-11","conditions":"Sepsis, Septic Shock","enrollment":600},{"nctId":"NCT04799626","phase":"","title":"Population Pharmacokinetics and Dosage Individualization of Antibiotics in Elderly Patients","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-04-01","conditions":"Elderly Infection","enrollment":500},{"nctId":"NCT03019965","phase":"NA","title":"Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis","status":"COMPLETED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2017-02-01","conditions":"Sepsis","enrollment":426},{"nctId":"NCT04895657","phase":"PHASE4","title":"Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-07-27","conditions":"Gram-Negative Infections","enrollment":56},{"nctId":"NCT04233996","phase":"PHASE4","title":"Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","startDate":"2019-06-05","conditions":"Febrile Neutropenia","enrollment":150},{"nctId":"NCT01198925","phase":"PHASE4","title":"Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2010-09-23","conditions":"Infectious Disease","enrollment":14},{"nctId":"NCT02466438","phase":"PHASE1","title":"Safety and Pharmacokinetics of Piperacillin-tazobactam Extended Infusion in Infants and Children (PIP-TAZO)","status":"UNKNOWN","sponsor":"St. Justine's Hospital","startDate":"2016-01","conditions":"Infection","enrollment":141},{"nctId":"NCT02463747","phase":"PHASE4","title":"Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2015-06","conditions":"Fever, Febrile Neutropenia","enrollment":110}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":94,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"piperacillin extended infusion","genericName":"piperacillin extended infusion","companyName":"University Hospital, Ghent","companyId":"university-hospital-ghent","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Piperacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious bacterial infections including pneumonia, intra-abdominal infections, and urinary tract infections, Pseudomonas aeruginosa infections, Febrile neutropenia in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}